American Journal of BioMedicine
Volume 10, Issue 4, October 14 2022, Pages 136-145 | http://dx.doi.org/10.18081/2333-5106/2022.10/136
Pingan Liu1*, Qingfeng Song, Chen-Lung Dong, Liu CY
Received April 30 2022 Revised August 22 2022 Accepted September 15 2022 Published October 14 2022
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by social deficits, communication inabilities and stereotypic behaviors. There are many suspected genetic causes of autism, but no cure has been proven to work to treat the disorder. Stem cells have been studied for their potential role in treating ASDs. Twenty-five children who fulfilled the autism criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [total scores below 30 indicate that an individual is “non-autistic,” while scores of 30 or above indicate that an individual is “autistic.” Individuals with scores above 30 are further subdivided into having “mild to moderate autism” (30 to 36.5) or “severe autism” (37 to 60)]. In this study only Childhood Autism Rating Scale (CARS) scores >37 was participated in this study. Harvested bone marrow from posterior iliac crest under light general anesthesia, for all patients under 10 kg collected 6 ml/kg while calculated the volume above 10-year age group (60 ml + [body weight in kg − 10] × 7 ml). Isolated mononuclear cells through Ficoll gradient under sterile condition in laminar flow class 2. The end products transmitted to sterile tube and injected slowly intrathecally. The same procedure was repeated 3 months later. The result after first bone marrow transplant showed that no severe side effects related with these procedures. The median CARS score decreasing from 52 to 44.2 (P =0.02). Beside this data the severity of autism spectrum disorder signs and symptoms were reduced. Inconclusion, this resulted data suggested that stem cell therapy for children with autism might be safe and effective. However, the evidence was compromised by the limitations in current study size, lacking standardized injection routes and doses of stem cells, as well as shortages in diagnostic tools and long period follow-up studies.
Keywords: Autism; Childhood Autism Rating Scale; Mental Disorders
Copyright © 2022 A Ragone, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Zwaigenbaum L, Bauman ML, Fein D, Pierce K, Buie T, Davis PA. Wagner S. Early Screening of Autism Spectrum Disorder: Recommendations for Practice and Research. Pediatrics 2015; 136:S41-S59.
2. Breidbord J, Croudace TJ. Reliability Generalization for Childhood Autism Rating Scale. Journal of Autism and Developmental Disorders 2013; 43:2855-2865.
3. Chawarska K, Klin A, Paul R, Macari S, Volkmar F. A prospective study of toddlers with ASD: Short-term diagnostic and cognitive outcomes. Journal of Child Psychology and Psychiatry and Allied Disciplines 2009; 50(10):1235-1245.
4. Dawkins T, Meyer AT, Van Bourgondien ME. The Relationship Between the Childhood Autism Rating Scale: Second Edition and Clinical Diagnosis Utilizing the DSM-IV-TR and the DSM-5. Journal of Autism and Developmental Disorders 2016; 667.
5. Gotham K, Pickles A, Lord C. Standardizing ADOS scores for a measure of severity in autism spectrum disorders. Journal of Autism and Developmental Disorders 2009; 39(5):693-705.
6. Kleinman JM, Robins DL, Ventola PE, et al. The modified checklist for autism in toddlers: A follow-up study investigating the early detection of autism spectrum disorders. Journal of Autism and Developmental Disorders 2008a; 38(5):827-839.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
8. Shaw KA, Maenner MJ, Baio J, et al. Early identification of autism spectrum disorder among children aged 4 years - early autism and developmental disabilities monitoring network, six sites, United States, 2016. MMWR Surveill Summ 2020; 69:1‐11.
9. Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 2008; 29:226‐231.
10. Ellison‐Wright Z, Boardman C. Diagnosis, and management of ASD in children and adolescents. Prog Neurol Psychiatry 2015; 19:28‐32.
11. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics 2010; 125:e17‐e23.
12. Cox CS Jr, Baumgartner JE, Harting MT, et al. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery 2011; 68:588‐600.
13. Ha S, Park H, Mahmood U, et al. Human adipose‐derived stem cells ameliorate repetitive behavior, social deficit and anxiety in a VPA‐induced autism mouse model. Behav Brain Res 2017; 317:479‐484.
14. Bansal H, Verma P, Agrawal A, et al. A short study report on bone marrow aspirate concentrates cell therapy in ten South Asian Indian patients with autism. J Stem Cells 2016; 11:25‐36.
15. Chez M, Lepage C, Parise C, et al. Safety and observations from a placebo‐controlled, crossover study to assess use of autologous umbilical cord blood stem cells to improve symptoms in children with autism. Stem Cells Translational Medicine 2018; 7:333‐341.
16. Parkhurst J, Kawa JM. Childhood autism rating scales Encyclopedia of Clinical Neuropsychology. Cham, Switzerland: Springer International Publishing 2018:1‐3.
17. Li H, Durbin R. Fast and accurate short read alignment with Burrows‐Wheeler transform. Bioinformatics 2009; 25:1754‐1760.
18. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7:248‐249.
19. Jarocha D, Milczarek O, Wedrychowicz A, et al. Continuous improvement after multiple mesenchymal stem cell transplantations in a patient with complete spinal cord injury. Cell Transplant 2015; 24:661‐672.
20. Hyman SL, Levy SE, Myers SM, Council on children with disabilities SOD behavioral P. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics 2020; 145: e20193447.
21. Qiu S, Lu Y, Li Y, et al. Prevalence of autism spectrum disorder in Asia: a systematic review and meta-analysis. Psychiatry Res 2020; 284:112679.
22. Lenroot RK, Yeung PK. Heterogeneity within autism spectrum disorders: what have we learned from neuroimaging studies? Front Hum Neurosci 2013; 7:733.
23. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells (Dayton, Ohio) 2007; 25:2739-49.
24. Sharifzadeh N, Ghasemi A, Tavakol Afshari J, et al. Intrathecal autologous bone marrow stem cell therapy in children with autism: a randomized controlled trial. Asia Pac Psychiatry 2021; 13:e12445.
25. Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med 2013; 11:196.
26. Dawson G, Sun JM, Baker J, Carpenter K, Compton S, Deaver M, et al. A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder. J Pediatr 2020; 222:164-73.e5.
27. Dawson G, Sun JM, Davlantis KS, Murias M, Franz L, Troy J, et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial. Stem Cells Transl Med 2017; 6:1332-9.
28. Levi AD, Anderson KD, Okonkwo DO, Park P, Bryce TN, Kurpad SN, et al. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma 2019; 36:891-902.
29. Guan J, Lin Y, Ji G. Cell type-specific gene network-based analysis depicts the heterogeneity of autism spectrum disorder. Front Cell Neurosci 2020; 14:59.
30. Min L, Liangwei S, Yongtao L, Ying H, Rucun G, Yulin C, et al. Stem cells for treatment of autism: safety and efficacy. J Clin Rehabilitative Tissue Engineering Res 2010; 14:5967-70.
31. Baio J. Prevalence of autism spectrum disorder among children aged 8 years-Autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014; 63:1-21.
32. Dawson G, Rogers S, Munson J et al. Randomized, controlled trial of an intervention for toddlers with autism: The early start Denver model. Pediatrics 2010; 125:e17-e23.
33. Young AMH, Chakrabarti B, Roberts D et al. From molecules to neural morphology: Understanding neuroinflammat ion in autism spectrum condition. Mol Autism 2016; 7:1-8.
34. Suzuki K, Sugihara G, Ouchi Y et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 2013; 70:49-58.
35. Lord C,Rutter M, DiLavore P et al. Autism Diagnostic Observation Schedule (ADOS-2). 2nd ed. Torrance, CA: Western Psychological Services, 2012.
36. Brugha TS, Doos L, Tempier A, Einfeld S, Howlin P. Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems. Int J Methods Psychiatr Res 2015; 24:99-115.
2. PDF XML
For any technique error please contact us.